ATE459653T1 - Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen - Google Patents

Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen

Info

Publication number
ATE459653T1
ATE459653T1 AT06795343T AT06795343T ATE459653T1 AT E459653 T1 ATE459653 T1 AT E459653T1 AT 06795343 T AT06795343 T AT 06795343T AT 06795343 T AT06795343 T AT 06795343T AT E459653 T1 ATE459653 T1 AT E459653T1
Authority
AT
Austria
Prior art keywords
antibodies
tumor cells
monoclonal anti
malignant tumor
treating malignant
Prior art date
Application number
AT06795343T
Other languages
English (en)
Inventor
Laurence Boumsell
Jean Kadouche
Armand Bensussan
Original Assignee
Inst Nat Sante Rech Med
Monoclonal Antibodies Therapeu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Monoclonal Antibodies Therapeu filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE459653T1 publication Critical patent/ATE459653T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06795343T 2005-06-15 2006-06-14 Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen ATE459653T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/154,262 US7736647B2 (en) 2005-06-15 2005-06-15 Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
PCT/IB2006/002331 WO2007000671A2 (en) 2005-06-15 2006-06-14 Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumour cells

Publications (1)

Publication Number Publication Date
ATE459653T1 true ATE459653T1 (de) 2010-03-15

Family

ID=37573538

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06795343T ATE459653T1 (de) 2005-06-15 2006-06-14 Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen

Country Status (10)

Country Link
US (2) US7736647B2 (de)
EP (1) EP1896507B1 (de)
JP (1) JP5185815B2 (de)
AT (1) ATE459653T1 (de)
CA (1) CA2612486A1 (de)
DE (1) DE602006012672D1 (de)
DK (1) DK1896507T3 (de)
ES (1) ES2341625T3 (de)
PL (1) PL1896507T3 (de)
WO (1) WO2007000671A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2340317A1 (de) * 2008-10-23 2011-07-06 F. Hoffmann-La Roche AG Bestimmung einer für immunglobulin codierenden nukleinsäure
RU2704802C2 (ru) 2009-07-22 2019-10-31 Актиниум Фармасьютикалз Инк. Способы получения радиоиммуноконъюгатов
US8734799B2 (en) 2010-04-13 2014-05-27 The Regents Of The University Of California Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
RU2632647C2 (ru) * 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
EP3559049B1 (de) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptidkonstrukte und anwendungen davon
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
TWI726879B (zh) 2015-05-04 2021-05-11 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
EP3325006A4 (de) 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York Verfahren zur behandlung von cd166-exprimierendem krebs
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
WO2017221883A1 (ja) 2016-06-20 2017-12-28 武田薬品工業株式会社 抗体-薬物コンジュゲート
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
AU2017378226A1 (en) 2016-12-14 2019-06-20 Janssen Biotech, Inc. CD8A-binding fibronectin type III domains
EP3554535A4 (de) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Pd-l1-bindende fibronectin-typ iii-domänen
EP3554561B1 (de) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137-bindende fibronectin-typ-iii-domänen
SG10202107429WA (en) 2017-01-06 2021-08-30 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
JP2020511130A (ja) 2017-03-09 2020-04-16 サイトメックス セラピューティクス インコーポレイテッド Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EP3762420A1 (de) 2018-03-09 2021-01-13 CytomX Therapeutics, Inc. Aktivierbare cd147-antikörper und verfahren zur herstellung und verwendung davon
US12097263B2 (en) * 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2019316103B2 (en) 2018-08-02 2026-02-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
KR102258014B1 (ko) * 2019-05-15 2021-05-27 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
KR102258015B1 (ko) * 2019-05-15 2021-05-27 강원대학교 산학협력단 암 줄기세포 세포막 단백질에 특이적인 항체 및 그 응용
CA3147690A1 (en) * 2019-07-19 2021-01-28 WuXi Biologics Ireland Limited Polypeptide complex for conjugation and use thereof
JP7764035B2 (ja) * 2019-08-19 2025-11-05 ウニベルシテート バーゼル 細胞治療の方法
WO2021061867A1 (en) 2019-09-23 2021-04-01 Cytomx Therapeutics, Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4045061A4 (de) * 2019-10-14 2024-04-17 ARO Biotherapeutics Company Cd71-bindende fibronectin-typ iii-domänen
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
KR20230128050A (ko) 2020-12-31 2023-09-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 근긴장성 이영양증을 치료하기위한 그의 용도
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
WO2023034409A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308626A (en) 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
JPH05505823A (ja) 1990-03-27 1993-08-26 ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ 細胞成長抑制法およびそれに有用な組成物
US5762932A (en) 1990-04-26 1998-06-09 University Of Iowa Research Foundation Combined treatment of iron depletion and IgG antibody
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1765868B1 (de) 2004-06-07 2016-04-20 MacroGenics, Inc. Antikörper gegen den transferrinrezeptor

Also Published As

Publication number Publication date
US8409573B2 (en) 2013-04-02
US7736647B2 (en) 2010-06-15
US20110311544A1 (en) 2011-12-22
PL1896507T3 (pl) 2010-08-31
DK1896507T3 (da) 2010-06-07
EP1896507A2 (de) 2008-03-12
JP5185815B2 (ja) 2013-04-17
EP1896507B1 (de) 2010-03-03
WO2007000671A3 (en) 2007-04-26
DE602006012672D1 (de) 2010-04-15
US20060286030A1 (en) 2006-12-21
ES2341625T3 (es) 2010-06-23
JP2009509497A (ja) 2009-03-12
CA2612486A1 (en) 2007-01-04
WO2007000671A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
ATE459653T1 (de) Monoklonale anti-cd71-antikörper und deren verwendung zur behandlung maligner tumorzellen
SG171690A1 (en) Treatment of protein degradation disorders
TW200740844A (en) Novel MAdCAM antibodies
PL1893196T5 (pl) Związek diarylohydantoinowy
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MA32140B1 (fr) Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
ATE551071T1 (de) Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
MX339682B (es) Anticuerpos monoclonales contra claudina-18 para el tratamiento de cancer.
EP1765391A4 (de) Bakterielle zusammensetzungen zur behandlung von krebs
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
TW200714604A (en) Substituted heterocycles and the uses thereof
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
EA200901249A1 (ru) Ингибиторы связывания протеинкиназ
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2008092002A3 (en) Compositions and methods for treating and diagnosing pancreatic cancer
MXPA05006507A (es) Inhibidores de ccxckr2 expresado en tumor humano.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1896507

Country of ref document: EP